Anti-CEP Therapeutic for Age Related Macular Degeneration


John W. Crabb, PhD
Robert G. Salomon, PhD
Bela Anand-Apte, MD, PhD
Quteba Ebrahem, MD
Kutralanathan Regnathan


What is it? What does it do?

Wet macular degeneration is the advanced stage of age-related macular degeneration (AMD) and affects approximately 10-15% of patients with AMD, yet accounts for more than 80% of all vision loss associated with the disease. Wet AMD is caused by abnormal blood vessel growth in the retina, known as choroidal neovascularization.

The invention is a therapeutic method for inhibiting angiogenesis (new blood vessel growth) by inhibiting one or more Carboxyethylpyrrole (CEP) protein adducts. CEP adducts demonstrate angiogenic properties and may play a role in CNV development that leads to wet AMD. This anti-CEP antibody has been shown to neutralize vessel growth stimulated by CEP in an in vivo model, and thus, could be a useful therapy for limiting CNV in AMD.

Why is it better?

CEP adducts stimulate angiogenesis in part via VEGF independent pathway, thus this anti-CEP therapeutic provides another method for limiting CNV.

What is its current status?

Monoclonal anti-CEP antibody has been shown to neutralize angiogenesis in mouse; further details can be found in 2006 PNAS publication – Ebrahem et al. “Carboxyethylpyrrole oxidative protein modifications stimulate neovascularization: Implications for age-related macular degeneration”

Get in Touch With Us